Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

ACET 12.18.2024

Full Press ReleaseSEC FilingsOur ACET Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
  • 12.31.2024 - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
  • 12.19.2024 - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Recent Filings

  • 12.19.2024 - EX-99.1 EX-99.1
  • 12.19.2024 - 8-K Current report
PDF Version

Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, fromEarly-Stage Researchto Successful Regulatory Approvals and Commercialization

REDWOOD CITY, Calif.&BOSTON--(BUSINESS WIRE)--Dec. 18, 2024--Adicet Bio, Inc.(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment ofJulie Maltzman, M.D. as Chief Medical Officer, effectiveJanuary 13, 2025.Dr. Maltzmanwill lead the Adicet clinical development strategy to advance Adicet’s robust autoimmune and oncology pipeline.

“We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the clinical development of multiple products across therapeutic areas notably in solid tumors and autoimmune diseases, from early-stage research to global approvals and commercialization, will be a big asset for Adicet as we advance our novel pipeline of allogeneic gamma delta CAR T cell therapies for multiple autoimmune and oncology indications,” saidChen Schor, President and Chief Executive Officer ofAdicet Bio. “We’re at an exciting point where we are seeing significant momentum in our clinical trial enrollment efforts, with an increasing number of sites activated and patients enrolling in both the ADI-001 and ADI-270 programs. This progress highlights the promising potential of our therapies. Julie’s expertise will help position us well in our goal for continued success in the development and regulatory progress of these novel therapies for patients.”

Dr. Maltzmansucceeds Dr.Francesco Galimiwho has completed his tenure at Adicet this month. “We thankDr. Galimifor his contributions and wish him all the best in his future endeavors,” Schor added.

“I am extremely honored and privileged to join the Adicet team during this pivotal time in the Company’s growth trajectory,” saidJulie Maltzman, M.D. “Having worked on the development of several transformative therapies, I believe Adicet’s novel allogeneic gamma delta CAR T cell platform has life-changing potential for patients with various oncologic and autoimmune diseases. I am inspired by the opportunity to help lead our efforts to bring these therapies in development to the many patients around the globe who are in dire need of a potential new curative treatment approach.”

Dr. Maltzmanhas broad experience, built over 20 years, leading clinical development efforts both in oncology and autoimmune diseases across all phases of drug development, from early Phase 1 through global regulatory filings, approvals and commercialization.

She joins Adicet from IconOVir Bio where she served as Chief Medical Officer leading, designing, and executing on a clinical development program focused on refractory solid tumors. Prior to that, she served as the VP, Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech. There,Dr. Maltzmanoversaw the successful worldwide registration and commercialization of the solid tumor blockbuster combination therapy Tecentriq+Avastin®and co-led the cross-functional team accountable for managing all Tecentriq®program activities including manufacturing, safety, biomarker and translational research, regulatory strategy, branding and positioning.Dr. Maltzmanalso served as the executive Co-Chair of their multifunctional, senior-level integratedCancerImmunotherapyCommittee (CITC) which brought together all key functions to articulate an integrated Roche Group Cancer Immunotherapy Strategic roadmap.

Dr. Maltzmanled early First-In-Human trials for rheumatoid arthritis with novel monoclonal antibodies while atMorphotek Inc.With additional leadership roles at flagship biopharma companies including Gilead and Glaxo SmithKline (GSK),Dr. Maltzmanhas designed and efficiently implemented clinical studies exceeding enrollment goals months earlier than anticipated, assisted with CMC (Chemistry, Manufacturing and Controls) initiatives to support clinical and regulatory submissions, conceptualized and negotiated multipleU.S.and EU labels, and established and built Medical and Medical Affairs functions including activating key opinion leader (KOL) and scientific educational initiatives to drive therapeutic awareness and adoption.

Dr. Maltzmanearned her M.D. from theUniversity of Colorado, completed her Internship and Residency in theDepartment of Internal Medicineat theUniversity of Chicago, and completed a Fellowship in theDivision of Hematology/Oncologyat theUniversity of Pennsylvania.

AboutAdicet Bio, Inc.

Adicet Bio, Inc.is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website athttps://www.adicetbio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: Adicet’s expected growth as a company; clinical development and regulatory progress of Adicet’s product candidates; the promising potential of Adicet’s product candidates for autoimmune and oncology indications; and the anticipated contribution ofDr. Maltzmanto Adicet’s business.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health emergencies on Adicet’s business and financial results, including with respect to disruptions to our preclinical and clinical studies, business operations, employee hiring and retention, and ability to raise additional capital; Adicet’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; that positive results, including interim results, from a preclinical or clinical study may not necessarily be predictive of the results of future or ongoing studies; clinical studies may fail to demonstrate adequate safety and efficacy of Adicet’s product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; and regulatory approval processes of theU.S. Food and Drug Administrationand comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable; and Adicet’s ability to meet production and product release expectations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Adicet’s most recent quarterly report on Form 10-Q and subsequent filings with theU.S. Securities and Exchange Commission(SEC), as well as discussions of potential risks, uncertainties, and other important factors in Adicet’s other filings with theSEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241218028991/en/

Adicet Bio, Inc.Investor and Media Contacts

Investors:Anne Bowdidgeabowdidge@adicetbio.com

Janhavi MohitePrecision AQ212-362-1200janhavi.mohite@precisionaq.com

Media:Kerry Beth Dalykbdaly@adicetbio.com

Source:Adicet Bio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com